Amlodipine News and Research

RSS
Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Dr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin Calcium Tablets

Dr. Reddy's Laboratories launches Amlodipine Besylate and Atorvastatin Calcium Tablets

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Calcium-channel blocker and antibiotic intake linked with small but greater risk of kidney injury

Calcium-channel blocker and antibiotic intake linked with small but greater risk of kidney injury

Study assesses relationship between BMI and CV events in hypertensive patients with diabetes

Study assesses relationship between BMI and CV events in hypertensive patients with diabetes

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive therapy touted for obese

BMI may influence which blood pressure treatments work best

BMI may influence which blood pressure treatments work best

Latest polypill trial yields largest improvements yet

Latest polypill trial yields largest improvements yet

No added benefit of aliskiren-amlodipine fixed drug combination for hypertension

No added benefit of aliskiren-amlodipine fixed drug combination for hypertension

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

Ranbaxy signs consent decree with U.S. FDA

Ranbaxy signs consent decree with U.S. FDA

Ranbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.

Ranbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Par Pharmaceutical reports second quarter total revenues of $224.2 million

Par Pharmaceutical reports second quarter total revenues of $224.2 million

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Mylan enters settlement agreement with Pfizer for Caduet Tablets litigation

Mylan enters settlement agreement with Pfizer for Caduet Tablets litigation

Combination therapy initially, best for blood pressure control: ACCELERATE study

Combination therapy initially, best for blood pressure control: ACCELERATE study

FDA approves Novartis' Amturnide for treatment of high blood pressure

FDA approves Novartis' Amturnide for treatment of high blood pressure